ViroScanner AI
Accelerating Viral Cures through Intelligent Molecular Synthesis
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in January 2026 by Amit Zul, ViroScanner AI operates with 1-10 employees. The company is currently in the Pre-Funding stage, focusing on R&D for its molecular screening platform.
Business overview
ViroScanner AI develops a high-performance molecular screening platform that leverages a combination of AI, computational chemistry, and proprietary optimization algorithms. This technology aims to accelerate viral cure development by bypassing traditional R&D timelines. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Drugs Discovery & Development market and serving the Pharmaceuticals segment within Healthcare & Life Sciences.
Log in to access full profile ›Company Intelligence Q&A
- When was ViroScanner AI founded?
- ViroScanner AI was founded in January 2026.
- Who is the founder of ViroScanner AI?
- Amit Zul is the founder of ViroScanner AI.
- What is ViroScanner AI's primary focus?
- ViroScanner AI focuses on accelerating viral cures through intelligent molecular synthesis using its high-performance molecular screening platform.
- What technology does ViroScanner AI utilize?
- ViroScanner AI utilizes a synergistic combination of AI, computational chemistry, and proprietary optimization algorithms.
- In which sector does ViroScanner AI primarily operate?
- ViroScanner AI's primary sector is Health Tech & Life Sciences, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.